Better Buy: Vertex Pharmaceuticals vs. Galapagos
Two of the hottest biotech companies this year are undoubtedly Vertex Pharmaceuticals (NASDAQ: VRTX) and Galapagos (NASDAQ: GLPG). For the former, the launch of a potential blockbuster drug for the treatment of cystic fibrosis would likely send shares to new levels. For the latter, a drug undergoing phase 3 clinical trials for multiple indications has witnessed promising top-line results.
With billions of sales potentially on the table for both companies, the stakes are arguably very high. Let's look at which of the two companies is a better buy for avid biotech investors.
Image source: Getty Images.
Source Fool.com
